摘要
目的 探讨紫杉醇脂质体联合奈达铂治疗中晚期宫颈癌放疗患者的临床疗效。方法 选择我院2012年1月~2014年6月收治的中晚期宫颈癌患者69例,依据随机数字表法分为观察组35例与对照组34例。对照组采用放疗治疗,观察组在对照组基础上采用紫杉醇脂质体联合奈达铂化疗治疗。两组患者均以21 d为1个治疗周期,连续治疗3个周期。比较两组患者治疗疗效、治疗前后QOL评分、Karnofsky评分、用药期间毒副反应的发生情况及血清鳞状细胞癌(SCC)、恶性肿瘤特异生长因子(TSGF)水平的变化。结果 观察组治疗有效率(71.43%)显著高于对照组(44.12%)(P〈0.05)。两组治疗后QOL和Karnofsky评分均较治疗前明显增加(P〈0.05),且观察组QOL和Karnofsky评分明显高于对照组(P〈0.05)。两组毒副反应发生率比较,差异无统计学意义(P〉0.05)。两组治疗后血清SCC、TSGF水平均较治疗前明显降低(P〈0.05),观察组治疗后血清SCC、TSGF水平明显低于对照组(P〈0.05)。结论 紫杉醇脂质体联合奈达铂对中晚期宫颈癌放疗患者疗效显著,其作用可能与降低血清SCC、TSGF水平有关。
Objective To investigate the clinical efficacy of advanced cervical cancer patients treated by radiotherapy combined with paclitaxel liposomal platinum nedaplatin. Methods In this study, 69 patients with advanced cervical cancer were selected from our hospital during January 2012 and June 2014. They were randomly divided into the observation group (35 cases) and the control group (34 cases). Patients in the control group were treated by radiation therapy, while those in the observation group were treated by combination of paclitaxel liposome with nedaplatin chemotherapy on the basis of radiotherapy. Patients in the two groups had 21d as a treatment cycle, and all had continuous 3 cycles of treatment. Effects of treatment, QOL and Karnofsky score before and after treatment, serum squamous-cell carcinoma (SCC) and tumor specific growth factor (TSGF) levels, and drug toxicity were compared between the two groups. Results The response rate (RR) of the observation group (71.43%) was significantly higher than that of the control group (44.12%) (P〈0.05). After treatment, the QOL and Karnofsky score in both groups increased significantly (P〈0.05). And the observation group had higher QOL and Karnofsky score than that of the control group after treatment (P 〈 0.05). There was no statistical difference in the incidence of adverse reaction be- tween the two groups (P〉 0.05). Serum SCC and TSGF levels in the two groups decreased significantly after treatment (P〈0.05), and the SCC and TSGF levels were lower in the observation group than the control group (P〈0.05). Conclusion Paclitaxel liposome combined with nedaplatin had significant effects on advanced cervical cancer patients who received radiotherapy simultaneously. Its role may be associated with the decreasing of serum SCC and TSGF levels.
出处
《肿瘤药学》
CAS
2016年第3期203-207,共5页
Anti-Tumor Pharmacy
关键词
紫杉醇脂质体
奈达铂
中晚期宫颈癌
放疗
疗效
Pachtaxel liposome
Nedaplatin
Advanced cervical cancer
Radiotherapy
Efficacy